Abstract 3736
Background
For decades, conventionally fractionated whole breast irradiation (CF-WBI) was used after breast conserving surgery (BCS). Pivotal phase 3 trials on hypofractionated-WBI (HF-WBI) showed its non-inferiority as compared to CF-WBI. However, younger patients (<60 years) are not currently worldwide treated with HF-WBI. The aim of this multi-center comparative study is to confirm the safety of HF-WBI in a real-life series of younger patients.
Methods
Between 2010 and 2016, a total of 786 patients aged less than 60 years old with early stage breast cancer were treated with postoperative WBI after BCS in three breast cancer centers: 340 underwent HF-WBI while 446 were treated with CF-WBI. Acute toxicity was evaluated at the end of WBI. Late toxicity was evaluated at 6, 12, 24, and 36 months.
Results
At univariate logistic analysis, hypofractionation showed a significant protective effect in terms of acute edema (p = 0.0001), acute wet desquamation (p = 0.009), chronic edema (p = 0.0001), chronic erythema/pigmentation (p = 0.0001), and breast fibrosis (p = 0.0002). At multivariate logistic analysis, hypofractionation was independent significant factor for acute edema (OR 0.09, 95% CI 0.02 to 0.48; p = 0.005), acute wet desquamation (OR 0.07, 95% CI 0.009 to 0.59; p = 0.014), and chronic edema (OR 0.18, 95% CI 0.04 to 0.75; p = 0.018). Significant association between individual characteristics and toxicity (grade 2 or more) are summarized in Table.Table:
215P
Toxicity | N | Protective factor | p-value | OR (95%CI) | Risk factor | p-value | OR (95%CI) |
---|---|---|---|---|---|---|---|
Acute edema | 43 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.001 | 0.09 (0.03-0.30) 0.16 (0.06-0.46) | Chemotherapy | 0.002 | 2.63 (1.42-4.90) |
Chronic edema | 50 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.003 | 0.20 (0.09-0.44) 0.31 (0.14-0.66) | EIC presence Boost dose >10 Gy Breast size >492 cc | 0.0001 0.032 0.003 | 3.0 (1.66-5.46) 9.02 (1.21-67.45) 2.67 (1.41-5.05) |
Acute erythema/ pigmentation | 163 | HER2 positive status Trastuzumab | 0.002 0.022 | 0.30 (0.14-0.63) 0.39 (0.18-0.87) | Smoking habits Boost dose >10 Gy Breast size >492 cc | 0.001 0.038 0.002 | 2.14 (1.37-3.32) 2.60 (1.06-6.41) 1.78 (1.24-2.54) |
Chronic erythema/ pigmentation | 110 | Hypofractionation Dmax/Prescribed dose° <107% | 0.0001 0.001 | 0.40 (0.25-0.63) 0.45 (0.28-0.73) | EIC presence Positive FSM Boost dose >10 Gy Breast size >492 cc | 0.0001 0.002 0.007 0.034 | 2.39 (1.54-3.71) 3.47 (1.56-7.71) 15.43 (2.08-114.3) 1.58 (1.04-2.41) |
Acute wet desquamation | 20 | Hypofractionation Dmax/Prescribed dose° <107% | 0.009 0.047 | 0.14 (0.03-0.61) 0.29 (0.08-0.99) | - | - | - |
Breast fibrosis | 117 | Hypofractionation Tumor grade Ki67 index Dmax/Prescribed dose° <107% | 0.0002 0.022 0.023 0.017 | 0.44 (0.29-0.68) 0.53 (0.31-0.92) 0.60 (0.38-0.93) 0.58 (0.37-0.91) | EIC presence Boost dose >10 Gy Breast size >492 cc | 0.0001 0.022 0.0001 | 3.03 (1.99-4.62) 6.76 (2.04-22.45) 2.84 (1.83-4.41) |
Conclusions
HF-WBI showed significantly improved toxicity outcomes in terms of both acute skin edema and wet desquamation, and chronic skin edema. HF-WBI after BCS should replace CF-WBI independently of age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4546 - Efficacy and toxicity of weekly carboplatin and paclitaxel as induction or palliative treatment in advanced esophageal cancer patients
Presenter: Femke de Man
Session: Poster Display session 2
Resources:
Abstract
5908 - Perioperative chemotherapy with Docetaxel, Oxaliplatin, Fluorouracil and Leucovorin (FLOT) versus Epirubicin, Platinum and Capecitabine or Flourouracil (EOX/ECF) in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma- Safety and response data from India.
Presenter: Tanuj Chawla
Session: Poster Display session 2
Resources:
Abstract
937 - Phase II Study of Preoperative Radiotherapy Combined with S-1 plus Cisplatin in Clinically Resectable Type 4 or Large Type 3 Gastric Cancer: OGSG1205
Presenter: Shunji Endo
Session: Poster Display session 2
Resources:
Abstract
1119 - Observational Study of the Peritoneal Washing Cytology Positive Gastric Cancer without Gross Peritoneal Metastasis Underwent Radical D2 Gastrectomy.
Presenter: Jun Eul Hwang
Session: Poster Display session 2
Resources:
Abstract
3744 - Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Presenter: Akira Miki
Session: Poster Display session 2
Resources:
Abstract
5091 - Multicenter Phase I/II Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (GMBH-STO-0114)
Presenter: Kathrin Heinrich
Session: Poster Display session 2
Resources:
Abstract
2891 - A phase I study of Docetaxel/Oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
Presenter: Kei Hosoda
Session: Poster Display session 2
Resources:
Abstract
2994 - Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: a prospective clinical study (Data updated)
Presenter: Mudan Yang
Session: Poster Display session 2
Resources:
Abstract
3000 - A multicenter phase II study of TAS-114 in combination with S-1 in patients with pre-treated advanced gastric cancer (EPOC1604)
Presenter: Daisuke Takahari
Session: Poster Display session 2
Resources:
Abstract
4653 - Impact of Pembrolizumab (pembro) Versus Paclitaxel on Health-Related Quality of Life (HRQoL) in Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer That Has Progressed After First-Line Chemotherapy (KEYNOTE-061)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract